MCID: SVR005
MIFTS: 50

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 55 15 72 33
Severe Preeclampsia 12 15
Severe Pre-Eclampsia, Antepartum Condition or Complication 72
Severe Pre-Eclampsia, Postpartum Condition or Complication 72
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 72

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 35 642.50
ICD10 33 O14.1
UMLS 72 C0156669 C0156672 C0156673 more

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following: SBP of 160mm HG or higher or DPB of 110mm HG or higher on 2 occasions at least 6 hours apart, proteinuria more than 5g in a 24-hour collection, pulmonary edema or cyanosis, oliguria, persistent headaches, epigastric pain and/or impaired liver function, thrombocytopenia, oligohydramnios, decreased fetal growth or placental abruption.

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to eclampsia and mild pre-eclampsia, and has symptoms including at least one of the following An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dalteparin and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include placenta, liver and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 257, show less)
# Related Disease Score Top Affiliating Genes
1 eclampsia 31.0 SERPINC1 PGF LGALS13 HLA-G ALB
2 mild pre-eclampsia 31.0 VCAM1 PGF LEP
3 antiphospholipid syndrome 30.9 VCAM1 SERPINC1 F5 APOH
4 end stage renal failure 30.5 LEP FN1 ALB
5 brain edema 30.3 VEGFA MMP9 ALB
6 placental insufficiency 30.3 VEGFA PGF LEP FGR
7 hellp syndrome 30.3 SERPINC1 PGF LGALS13 GPT F5 APOH
8 patau syndrome 30.0 PGF LGALS13
9 proteasome-associated autoinflammatory syndrome 1 30.0 VCAM1 MMP9 ALB
10 liver disease 29.8 LEPR LEP GPT ALB
11 liver cirrhosis 29.7 SERPINC1 LEP GPT ALB
12 glucose intolerance 29.7 RBP4 LEPR LEP
13 amaurosis fugax 29.6 MMP9 F5
14 homocysteinemia 29.3 SERPINC1 F5 ALB
15 thrombophilia due to thrombin defect 29.2 SERPINC1 F5 APOH
16 pre-eclampsia 29.2 VEGFA VCAM1 SERPINC1 PGF LGALS13 LEP
17 thrombophilia 29.1 SERPINC1 F5 APOH
18 placental abruption 29.1 SERPINC1 PGF F5 APOH
19 endocarditis 29.1 VCAM1 SERPINC1 APOH ALB
20 intracranial hypertension 28.9 SERPINC1 F5 APOH
21 antithrombin iii deficiency 28.8 SERPINC1 F5 APOH
22 thrombosis 28.8 SERPINC1 F5 APOH
23 thrombophilia due to activated protein c resistance 28.8 SERPINC1 F5 APOH
24 pulmonary embolism 28.7 SERPINC1 F5 APOH ALB
25 protein s deficiency 28.6 SERPINC1 F5 APOH
26 budd-chiari syndrome 28.6 SERPINC1 F5 APOH
27 placenta disease 28.2 SERPINC1 PGF F5 APOH
28 vascular disease 27.4 VEGFA VCAM1 SERPINC1 MMP9 F5 APOH
29 severe nonproliferative diabetic retinopathy 10.6 VEGFA ALB
30 angiokeratoma circumscriptum 10.5 VEGFA MMP9
31 acroosteolysis 10.5 VEGFA ALB
32 hepatic tuberculosis 10.5 GPT ALB
33 villous adenocarcinoma 10.5 MMP9 FN1
34 kwashiorkor 10.5 GPT ALB
35 adamantinous craniopharyngioma 10.4 VEGFA MMP9
36 balanitis xerotica obliterans 10.4 VEGFA APLN
37 trypanosomiasis 10.4 VCAM1 HLA-G ALB
38 protein-energy malnutrition 10.4 LEP GPT ALB
39 hepatic coma 10.4 GPT ALB
40 portal hypertension 10.4 VEGFA GPT ALB
41 sick building syndrome 10.4 VEGFA MMP9 LEP
42 thrombocytopenia 10.4
43 lipoblastoma 10.4 LEPR LEP
44 pulmonary edema 10.4
45 respiratory distress syndrome in premature infants 10.3
46 disseminated intravascular coagulation 10.3
47 newborn respiratory distress syndrome 10.3
48 acute kidney failure 10.3
49 microvascular complications of diabetes 1 10.3 VEGFA VCAM1 MMP9
50 parotitis 10.3 MMP9 ALB
51 non-secretory myeloma 10.3 FN1 ALB
52 gastrointestinal system cancer 10.3 VEGFA MMP9 ALB
53 respiratory system disease 10.3 VEGFA MMP9 ALB
54 hypertension, essential 10.3
55 retinal detachment 10.3
56 hydatidiform mole, recurrent, 1 10.3
57 yemenite deaf-blind hypopigmentation syndrome 10.3
58 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.3
59 hydrops, lactic acidosis, and sideroblastic anemia 10.3
60 deficiency anemia 10.3
61 gestational trophoblastic neoplasm 10.3
62 endocrine gland cancer 10.3 VEGFA MMP9 ALB
63 fournier gangrene 10.2 SERPINC1 ALB
64 gastrointestinal system disease 10.2 VEGFA MMP9 ALB
65 acquired metabolic disease 10.2 LEPR LEP ALB
66 nervous system disease 10.2 VEGFA MMP9 ALB
67 retinal vascular disease 10.2 VEGFA PGF ALB
68 asphyxia neonatorum 10.2
69 hemolytic anemia 10.2
70 chromosomal triplication 10.2
71 klatskin's tumor 10.2 MMP9 ALB
72 pain agnosia 10.1
73 oligohydramnios 10.1
74 migraine with or without aura 1 10.1
75 thrombotic thrombocytopenic purpura 10.1
76 respiratory failure 10.1
77 cortical blindness 10.1
78 purpura 10.1
79 kidney disease 10.1
80 triploidy 10.1
81 headache 10.1
82 partial hydatidiform mole 10.1
83 maturity-onset diabetes of the young, type 1 10.1 LEP APLN ALB
84 thrombotic microangiopathy 10.0
85 neovascular glaucoma 10.0 VEGFA PGF
86 subendocardial myocardial infarction 10.0 VCAM1 SERPINC1
87 microvascular complications of diabetes 5 10.0 VEGFA VCAM1 PGF ALB
88 autoimmune disease 10.0
89 body mass index quantitative trait locus 1 10.0
90 creatinine clearance quantitative trait locus 10.0
91 amnestic disorder 10.0
92 placenta praevia 10.0
93 chronic kidney disease 10.0
94 atrial standstill 1 10.0
95 renal cell carcinoma, nonpapillary 10.0
96 pheochromocytoma 10.0
97 neural tube defects 10.0
98 preeclampsia/eclampsia 1 10.0
99 enterocolitis 10.0
100 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
101 thrombocytopenia-absent radius syndrome 10.0
102 helicobacter pylori infection 10.0
103 patent ductus arteriosus 1 10.0
104 preeclampsia/eclampsia 4 10.0
105 preeclampsia/eclampsia 5 10.0
106 peripartum cardiomyopathy 10.0
107 adrenal gland pheochromocytoma 10.0
108 cardiac arrest 10.0
109 hemiplegia 10.0
110 adult respiratory distress syndrome 10.0
111 hemopericardium 10.0
112 cardiac tamponade 10.0
113 gestational diabetes 10.0
114 pericardial effusion 10.0
115 nephrotic syndrome 10.0
116 blood coagulation disease 10.0
117 hemolytic-uremic syndrome 10.0
118 acute kidney tubular necrosis 10.0
119 hypothyroidism 10.0
120 hyperuricemia 10.0
121 membranoproliferative glomerulonephritis 10.0
122 glomerulonephritis 10.0
123 cranial nerve palsy 10.0
124 congestive heart failure 10.0
125 scotoma 10.0
126 hypertensive encephalopathy 10.0
127 fatty liver disease 10.0
128 47,xyy 10.0
129 prothrombin-related thrombophilia 10.0
130 sickle cell disease 10.0
131 48,xyyy 10.0
132 aortic coarctation 10.0
133 bronchopulmonary dysplasia 10.0
134 cytokine deficiency 10.0
135 diploid-triploid mosaicism 10.0
136 gestational trophoblastic tumor 10.0
137 encephalopathy 10.0
138 hypoxia 10.0
139 infantile liver failure syndrome 1 9.9 GPT ALB
140 ovarian hyperstimulation syndrome 9.9 VEGFA F5 ALB
141 peripheral vascular disease 9.9 VEGFA VCAM1 SERPINC1 ALB
142 may-thurner syndrome 9.9 F5 APOH
143 myasthenia gravis 9.9
144 ocular motor apraxia 9.9
145 aspiration pneumonia 9.9
146 chorioamnionitis 9.9
147 endometritis 9.9
148 pancytopenia 9.9
149 von willebrand's disease 9.9
150 amenorrhea 9.9
151 acute pancreatitis 9.9
152 anuria 9.9
153 systemic scleroderma 9.9
154 hyperglycemia 9.9
155 pancreatitis 9.9
156 postpartum depression 9.9
157 acute respiratory distress syndrome 9.9
158 fetal edema 9.9
159 hereditary antithrombin deficiency 9.9
160 hydrops fetalis 9.9
161 inflammatory myopathy with abundant macrophages 9.9
162 acanthamoeba keratitis 9.9 F5 APOH
163 acute liver failure 9.9 GPT F5 ALB
164 intestinal disease 9.9 VEGFA F5 ALB
165 sudden sensorineural hearing loss 9.8 F5 APOH
166 cerebral sinovenous thrombosis 9.8 F5 APOH
167 alzheimer disease 9.7
168 total anomalous pulmonary venous return 1 9.7
169 colorectal cancer 9.7
170 fibromuscular dysplasia 9.7
171 hypercholesterolemia, familial, 1 9.7
172 hypertriglyceridemia, familial 9.7
173 chromosome 2q35 duplication syndrome 9.7
174 down syndrome 9.7
175 anemia, autoimmune hemolytic 9.7
176 insulin-like growth factor i 9.7
177 stroke, ischemic 9.7
178 anxiety 9.7
179 graft-versus-host disease 9.7
180 leptin deficiency or dysfunction 9.7
181 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
182 adrenal cortical carcinoma 9.7
183 metabolic acidosis 9.7
184 paraganglioma 9.7
185 paroxysmal nocturnal hemoglobinuria 9.7
186 polycystic kidney disease 9.7
187 cholelithiasis 9.7
188 renal hypertension 9.7
189 gastric ulcer 9.7
190 malignant hypertension 9.7
191 choledocholithiasis 9.7
192 multicentric reticulohistiocytosis 9.7
193 allergic hypersensitivity disease 9.7
194 acute cystitis 9.7
195 cholestasis 9.7
196 hepatic infarction 9.7
197 papilledema 9.7
198 mitral valve stenosis 9.7
199 optic nerve disease 9.7
200 sex cord-gonadal stromal tumor 9.7
201 myeloproliferative neoplasm 9.7
202 thrombocytosis 9.7
203 iron metabolism disease 9.7
204 lipid metabolism disorder 9.7
205 neurilemmoma 9.7
206 neurilemmoma of the fifth cranial nerve 9.7
207 aspiration pneumonitis 9.7
208 ischemia 9.7
209 cellulitis 9.7
210 hemoglobinuria 9.7
211 paraplegia 9.7
212 hyperthyroidism 9.7
213 periodontitis 9.7
214 appendicitis 9.7
215 polyhydramnios 9.7
216 lung disease 9.7
217 neuropathy 9.7
218 autosomal dominant polycystic kidney disease 9.7
219 krukenberg carcinoma 9.7
220 polyarteritis nodosa 9.7
221 hypoglycemia 9.7
222 pulmonary venous return anomaly 9.7
223 transposition of the great arteries 9.7
224 depression 9.7
225 nonsyndromic paraganglioma 9.7
226 dysphagia 9.7
227 bicornuate uterus 9.7
228 pik3ca-related overgrowth syndrome 9.7
229 pregnancy loss, recurrent 1 9.7 HLA-G F5 APOH
230 sticky platelet syndrome 9.7 SERPINC1 F5
231 catastrophic antiphospholipid syndrome 9.7 F5 APOH
232 sagittal sinus thrombosis 9.7 SERPINC1 F5
233 cerebrovascular disease 9.7 VCAM1 MMP9 F5
234 intermittent claudication 9.7 VEGFA SERPINC1 APOH ALB
235 dysfibrinogenemia 9.6 SERPINC1 F5 ALB
236 pulmonary artery disease 9.6 SERPINC1 F5 ALB
237 body mass index quantitative trait locus 11 9.5 RBP4 LEPR LEP GPT APLN
238 malaria 9.5 VEGFA VCAM1 SERPINC1 MMP9 ALB
239 vein disease 9.4 VEGFA SERPINC1 F5 ALB
240 spinal cord infarction 9.4 SERPINC1 F5 APOH
241 prothrombin deficiency, congenital 9.3 SERPINC1 F5 APOH
242 thrombophlebitis 9.3 SERPINC1 F5 APOH
243 peripheral vertigo 9.3 SERPINC1 F5 APOH
244 intracranial thrombosis 9.3 SERPINC1 F5 APOH
245 factor xii deficiency 9.3 SERPINC1 F5 APOH
246 legg-calve-perthes disease 9.3 SERPINC1 F5 APOH
247 portal vein thrombosis 9.3 SERPINC1 F5 APOH
248 patent foramen ovale 9.3 SERPINC1 F5 APOH
249 varicose veins 9.3 VEGFA SERPINC1 MMP9 F5
250 central retinal vein occlusion 9.2 VEGFA SERPINC1 F5 APOH
251 retinal vein occlusion 9.2 VEGFA SERPINC1 F5 APOH
252 retinal artery occlusion 9.2 VEGFA SERPINC1 F5 APOH
253 diabetes mellitus, noninsulin-dependent 9.1 VCAM1 RBP4 LEPR LEP GPT APLN
254 arteries, anomalies of 8.9 VEGFA VCAM1 SERPINC1 PGF MMP9 LEP
255 ischemic colitis 8.8 VEGFA SERPINC1 MMP9 F5 APOH
256 retinal vascular occlusion 8.7 VEGFA SERPINC1 PGF F5 APOH
257 myocardial infarction 8.5 VEGFA SERPINC1 PGF MMP9 F5 ALB

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

Symptoms:

12 (showing 1, show less)
  • at least one of the following

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

46 (showing 12, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ALB APLN APOH F5 FN1 HLA-G
2 cardiovascular system MP:0005385 10.29 APLN F5 FGR FN1 LEP LEPR
3 embryo MP:0005380 10.15 APLN F5 FN1 LEP LEPR PGF
4 hematopoietic system MP:0005397 10.13 FGR FN1 HLA-G LEP LEPR MMP9
5 immune system MP:0005387 10.13 FGR FN1 HLA-G LEP LEPR MMP9
6 muscle MP:0005369 9.92 ALB APLN FN1 LEP LEPR MMP9
7 liver/biliary system MP:0005370 9.91 ALB F5 FN1 LEP LEPR SERPINC1
8 limbs/digits/tail MP:0005371 9.88 FN1 LEP LEPR MMP9 RBP4 VEGFA
9 neoplasm MP:0002006 9.8 ALB FN1 LEP LEPR MMP9 PGF
10 renal/urinary system MP:0005367 9.7 ALB LEP LEPR MMP9 RBP4 SERPINC1
11 reproductive system MP:0005389 9.56 FN1 LEP LEPR MMP9 RBP4 SERPINC1
12 vision/eye MP:0005391 9.23 APLN LEP LEPR MMP9 PGF RBP4

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 164, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Ephedrine Approved Phase 4 299-42-3 9294
3
Pseudoephedrine Approved Phase 4 90-82-4 7028
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
leucovorin Approved Phase 4 58-05-9 143 6006
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Captopril Approved Phase 4 62571-86-2 44093
9
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
10
Azithromycin Approved Phase 4 83905-01-5 447043 55185
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12 Pharmaceutical Solutions Phase 4
13 Antibodies Phase 4
14 Immunoglobulins Phase 4
15 Antibodies, Antiphospholipid Phase 4
16 Anti-Infective Agents Phase 4
17 Heparin, Low-Molecular-Weight Phase 4
18 Adrenergic alpha-2 Receptor Agonists Phase 4
19 Adrenergic Agonists Phase 4
20 Adrenergic alpha-Agonists Phase 4
21 Sympatholytics Phase 4
22 Central Nervous System Stimulants Phase 4
23 Vasoconstrictor Agents Phase 4
24 Micronutrients Phase 4
25 Trace Elements Phase 4
26 Vitamin B9 Phase 4
27 Hematinics Phase 4
28 Folate Phase 4
29 Vitamin B Complex Phase 4
30 Nutrients Phase 4
31 Natriuretic Agents Phase 4
32 diuretics Phase 4
33 Sodium Potassium Chloride Symporter Inhibitors Phase 4
34 Angiotensin-Converting Enzyme Inhibitors Phase 4
35 Iron Supplement Phase 4
36 Lactoferrin Phase 4
37 Respiratory System Agents Phase 4
38 Nasal Decongestants Phase 4
39 Anti-Asthmatic Agents Phase 4
40 Bronchodilator Agents Phase 4
41
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
42
Misoprostol Approved Phase 3 59122-46-2 5282381
43
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
44
Carbetocin Approved, Investigational Phase 3 37025-55-1 16681432 71715
45
Digoxin Approved Phase 2, Phase 3 20830-75-5 30322 2724385
46
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
47
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
48
Titanium dioxide Approved Phase 3 13463-67-7
49
Povidone Approved Phase 3 9003-39-8
50
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
51 Urapidil Investigational Phase 3 34661-75-1
52 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
53 Citrate Phase 2, Phase 3
54 Phosphodiesterase Inhibitors Phase 2, Phase 3
55 Chelating Agents Phase 2, Phase 3
56 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
57 Gastrointestinal Agents Phase 3
58 Antacids Phase 3
59 Oxytocics Phase 3
60 Anti-Ulcer Agents Phase 3
61 Acetylsalicylic acid lysinate Phase 3
62 Cardiotonic Agents Phase 2, Phase 3
63 Immunoglobulin Fab Fragments Phase 2, Phase 3
64 Anesthetics, Local Phase 3
65 Serotonin Receptor Agonists Phase 3
66 Serotonin Agents Phase 3
67 Analgesics, Non-Narcotic Phase 3
68 Cyclooxygenase Inhibitors Phase 3
69 Anti-Inflammatory Agents, Non-Steroidal Phase 3
70 Anti-Inflammatory Agents Phase 3
71 Antipyretics Phase 3
72 Antirheumatic Agents Phase 3
73 Protective Agents Phase 3
74 Fibrinolytic Agents Phase 3
75 Platelet Aggregation Inhibitors Phase 3
76 Radiation-Protective Agents Phase 3
77
Triacetin Phase 3 102-76-1 5541
78 Sunscreening Agents Phase 3
79
Ethyl cellulose Phase 3 9004-57-3 24832091
80 Dermatologic Agents Phase 3
81 Photosensitizing Agents Phase 3
82
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
83
Hydralazine Approved Phase 2 86-54-4 3637
84
Dexmedetomidine Approved, Vet_approved Phase 2 113775-47-6 68602 5311068
85
Remifentanil Approved Phase 2 132875-61-7 60815
86
Acetaminophen Approved Phase 2 103-90-2 1983
87
Ibuprofen Approved Phase 2 15687-27-1 3672
88
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
89
Oxycodone Approved, Illicit, Investigational Phase 2 76-42-6 5284603
90
Ketorolac Approved Phase 2 74103-06-3, 66635-83-4 3826
91
Pravastatin Approved Phase 2 81093-37-0 54687
92
Certolizumab pegol Approved Phase 2 428863-50-7
93 Rosuvastatin Calcium Phase 1, Phase 2 147098-20-2
94 Hypnotics and Sedatives Phase 2
95 Lipid Regulating Agents Phase 2
96 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
97 Hypolipidemic Agents Phase 2
98 Antimetabolites Phase 2
99 Anticholesteremic Agents Phase 2
100 Immunologic Factors Phase 2
101 calcium heparin Phase 2
102 Narcotics Phase 2
103 Analgesics, Opioid Phase 2
104 Ketorolac Tromethamine Phase 2
105 Immunosuppressive Agents Phase 2
106 Angiogenesis Inducing Agents Phase 2
107
Methocarbamol Approved, Vet_approved Phase 1 532-03-6 4107
108
Vitamin C Approved, Nutraceutical Phase 1 50-81-7 54670067 5785
109 Antioxidants Phase 1
110 Vitamins Phase 1
111 Neuromuscular Agents Phase 1
112
Methyldopa Approved 555-30-6 38853
113
Protein C Approved
114
Nimodipine Approved, Investigational 66085-59-4 4497
115
Hydrocortisone Approved, Vet_approved 50-23-7 5754
116
Hydrocortisone acetate Approved, Vet_approved 50-03-3
117
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
118
Testosterone Approved, Experimental, Investigational 481-30-1, 58-22-0 6013 10204
119
Testosterone enanthate Approved 315-37-7 9416
120
Methyltestosterone Approved 58-18-4 6010
121
Testosterone undecanoate Approved, Investigational 5949-44-0
122
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
123
Bupivacaine Approved, Investigational 2180-92-9, 38396-39-3 2474
124
Thrombin Approved, Investigational
125
Vitamin D3 Approved, Nutraceutical 67-97-0 6221 5280795
126
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
127
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
128
Aspartic acid Approved, Nutraceutical 56-84-8 5960
129
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896
130
Vitamin E Approved, Nutraceutical, Vet_approved 59-02-9 14985
131
Vitamin A Approved, Nutraceutical, Vet_approved 22737-96-8, 11103-57-4, 68-26-8 9904001 445354